Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000211909 | SCV000209512 | uncertain significance | not provided | 2023-03-21 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 29642553, 18199528) |
| Ambry Genetics | RCV000159548 | SCV000216891 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-01-19 | criteria provided, single submitter | clinical testing | The p.V1099I variant (also known as c.3295G>A), located in coding exon 15 of the APC gene, results from a G to A substitution at nucleotide position 3295. The valine at codon 1099 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Invitae | RCV003534405 | SCV000819007 | uncertain significance | Familial adenomatous polyposis 1 | 2024-01-15 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 1099 of the APC protein (p.Val1099Ile). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with polyposis (Invitae). ClinVar contains an entry for this variant (Variation ID: 181800). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt APC protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Mendelics | RCV000691255 | SCV000838103 | uncertain significance | Familial adenomatous polyposis 1 | 2018-07-02 | criteria provided, single submitter | clinical testing | |
| Color Diagnostics, |
RCV000159548 | SCV000905976 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-11-16 | criteria provided, single submitter | clinical testing | This missense variant replaces valine with isoleucine at codon 1099 of the APC protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with APC-related disorders in the literature. This variant has been identified in 1/31408 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
| Baylor Genetics | RCV000691255 | SCV004199676 | uncertain significance | Familial adenomatous polyposis 1 | 2023-10-05 | criteria provided, single submitter | clinical testing |